Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
92.19 EUR | +0.38% | +3.71% | +2.66% |
04-29 | SANOFI : Jefferies reiterates its recommendation on the stock | CF |
04-29 | SANOFI : Deutsche Bank gives a Sell rating | ZD |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.66% | 123B | |
+26.47% | 664B | |
+25.71% | 567B | |
-6.33% | 354B | |
+19.35% | 330B | |
+4.23% | 286B | |
+13.58% | 234B | |
+4.57% | 199B | |
-10.10% | 196B | |
-4.04% | 148B |
- Stock Market
- Equities
- SAN Stock
- News Sanofi
- Sanofi : Phase 3 Study of Rilzabrutinib for Rare Autoimmune Skin Condition Fails to Meet Primary, Secondary Endpoints